Investors

Oncopeptides strives to ensure that analysts, investors, shareholders and financial media are provided with correct information to enhance understanding of our operations.

Nasdaq Stockholm

Price

Change

Latest investor news

March 23, 2026

CEO Sofia Heigis presented at Redeye event Commercialization in Life Science

Investor

March 20, 2026

Sofia Heigis presented and interviewed at Stockholm Corporate Finance Life Science Days

Investor

March 11, 2026

CEO Sofia Heigis presents Oncopeptides at Aktiespararna

Investor

March 5, 2026

Biostock: presentation and interview with Sofia Heigis

Investor

February 20, 2026

Oncopeptides CEO Sofia Heigis interviewed by Redeye about Q4 and the new share issue

Investor

January 19, 2026

CEO Sofia Heigis interviewed by Redeye

Investor

November 27, 2025

Oncopeptides presented at Stora Aktiedagarna – an Aktiespararna event in Stockholm

Investor

November 13, 2025

VIDEO NOW AVAILABLE: Oncopeptides hosted Capital Markets Update November 13

Investor

April 28, 2026

Oncopeptides publishes the 2025 Annual Report

Investor

Regulatory

April 16, 2026

Annual General Meeting in Oncopeptides

April 13, 2026

Preclinical data on novel NK-Cell engager to be presented at the AACR Annual Meeting 2026

March 31, 2026

Number of shares and votes in Oncopeptides

No upcoming events

Investor Relations Contact

David Augustsson, MSc

Director of IR and Communications

ir@oncopeptides.com

+46 762 29 38 68

Investors

Latest investor news

Investor Relations Contact

More investor information

The share

General Meeting

Financial Reports

Financial Calendar